Utilização da metformina como fármaco hipolipemiante em doentes não diabéticos
2004
OBJECTIVE: To evaluate the effect of therapy with metformin on the lipid profile of dyslipi- demic, non-diabetic patients. METHODS: We studied the subgroup of non- diabetic patients from our Lipidology / Dyslipi- demia outpatient clinic who were treated with metformin as first lipid lowering drug (n=17), and evaluated the lipid profile before and 3 mon- ths after introducing the drug. We compared the baseline characteristics of this group with those of a sample of non-diabetic dyslipidemic patients treated differently. RESULTS: Three months after introducing metformin, there was a 41,8% significant re- duction of triglycerides (p=0.006), as well as a 10.4% reduction of total cholesterol and a 5.9% raise of HDL cholesterol, which did not reach statistical significance. LDL cholesterol did not vary significantely. The non-diabetic patients who were treated with metformin had lower mean HDL choles- terol and higher mean triglycerides than the other non-diabetics. CONCLUSION: Metformin emerges as a good lipid-lowering drug in non-diabetic patients, particularly for patients with hypertriglyce- ridemia and other features of the metabolic
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
13
References
0
Citations
NaN
KQI